Bacteriotherapy for inflammatory bowel disease

Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai

Research output: Contribution to journalReview articlepeer-review

Abstract

The number of patients with inflammatory bowel disease is rapidly increasing in developed countries. The main cause of this increase is thought not to be genetic, but secondary to rapidly modernized environmental change. Changes in the environment have been detrimental to enteric probiotics useful for fermentation, inducing an increase in pathobionts that survive by means other than fermentation. This dysregulated microbiota composition, the so-called dysbiosis, is believed to have increased the incidence of inflammatory bowel disease. Bacteriotherapy, a treatment that prophylactically and therapeutically corrects the composition of disturbed intestinal microbiota, is a promising recent development. In fact, fecal microbiome transplantation for recurrent Clostridioides difficile infection in 2013 was a significant contribution for bacteriotherapy. In this paper, we comprehensively review bacteriotherapy in an easy-to-understand format.

Original languageEnglish
Article number3
JournalInflammation and Regeneration
Volume41
Issue number1
DOIs
Publication statusPublished - 2021 Dec

Keywords

  • Bacteriotherapy
  • Clostridioides (Clostridium) difficile infection
  • Dysbiosis
  • Fecal microbiome transplantation
  • Prebiotics
  • Probiotics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cell Biology

Fingerprint Dive into the research topics of 'Bacteriotherapy for inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this